Takeda Pharmaceutical CEO Christophe Weber highlighted the importance of gaining a strong foothold in the world’s largest pharma market at…
REGULATORY
ViiV’s HIV Drug Juluca to Join NHI Price List on Dec. 12
The health ministry’s Central Social Insurance Medical Council (Chuikyo) on December 5 approved the expedited NHI price listing of ViiV Healthcare’s dual HIV therapy Juluca (dolutegravir + rilpivirine). The drug will be listed on December 12. The drug, which received…
To read the full story
Related Article
- HIV Drug Juluca Gets Japan Approval: ViiV
November 27, 2018
REGULATORY
- Spinraza under PMDA Risk Review for Hydrocephalus
December 10, 2018
- R&D Tax Credit Refit Taking Shape; Open Innovation Scheme Likely to Cover Research Commissioned to Big Firms
December 10, 2018
- Council Holds Off Nonprescription Switches of PPIs Despite Public Support
December 10, 2018
- JPMA Official Renews Call for Use of “Specified Clinical Research” Data in Application Dossiers
December 7, 2018
- Burden on Clinical Research Core Hospitals Should Be Reduced: HSC Panel Chair
December 7, 2018
While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…
Daiichi Sankyo and GlaxoSmithKline recently announced that they have agreed to dissolve their joint venture company, Japan Vaccine. The failure of this model of joint venture between a major Japanese and foreign drug maker in just six years is disappointing.Over…
To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…